



## DEPARTMENT OF HEALTH &amp; HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857Re: Reminyl  
Docket No. 01E-0364

The Honorable James. E. Rogan  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 2327  
Arlington, VA 22202

DEC 10 2002

Dear Director Rogan:


This is in regard to the patent term extension application for U.S. Patent No. 4,663,318 filed by Janssen Research Foundation under 35 U.S.C. § 156. The patent claims the human drug product Reminyl (galatamine hydrobromide), new drug application NDA 21-169.

In the February 28, 2002, issue of the Federal Register (67 Fed. Reg. 9301), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before August 27, 2002, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,



Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: John Richards, Esq.  
Ladas & Pary  
26 West 61th St.  
New York, NY 10023